FDA Updates Lumateperone Label With Relapse-Prevention Data - Top-Institutions - MDSpire

FDA Updates Lumateperone Label With Relapse-Prevention Data

Label update incorporates randomized withdrawal trial findings showing delayed time to relapse and consistent safety profile in schizophrenia

  • By

  • Kathryn Wighton

  • April 29, 2026

  • 2 min

Share

Top Institutions in Psychiatry

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Mental Health (NIMH)
    National Institute of Mental Health (NIMH)

    Bethesda, MD

    Key Differentiators

    • Psychiatry
    • Neuroscience
    • Clinical Trials

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Psychiatry
    • Clinical Research
    • Neuropharmacology

  • #3

    Massachusetts General Hospital (MGH) / Harvard Medical School
    Massachusetts General Hospital (MGH) / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Psychiatry
    • Neuroscience
    • Psychopharmacology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Psychiatry
    • Clinical Neuroscience
    • Psychopharmacology

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Psychiatry
    • Neuroscience
    • Clinical Trials

Original Source(s)

FDA Updates Lumateperone Label With Relapse-Prevention Data

  • by Kathryn Wighton

  • April 29, 2026

Related Content

Urine Markers May Aid Psych Diagnosis

Genetically predicted urinary metabolite levels were associated with schizophrenia, bipolar disorder, attention-deficit/hyperactivity disorder, and anorexia nervosa in a Mendelian randomization analysis.

Artificial Intelligence Centrality in Psychotic Delusions and Violence Risk in Forensic Psychiatry: Retrospective Observational Study of Judicial Decisions

Body Dysmorphic Symptoms Linked to Brain Structure

Researchers reported gender-specific associations in visual and limbic brain regions among healthy adults with subclinical body dysmorphic symptoms.